We are Allyl(triphenyl)phosphonium bromide CAS:1560-54-9 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name:Allyl(triphenyl)phosphonium bromide
Allyl triphenyl phosphonium bromide
Physical and Chemical Properties:
Melting Point 222-225 °C(lit.)
Molecular Formula C21H20BrP
Molecular Weight 383.261
Exact Mass 382.048584
Water Solubility decomposes
Appearance:Whitewhite crystalline powder
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Phase-transfer catalyst in chemical reactions.
Our quaternary ammonium salt series products reach more than 200 kinds, and the product categories cover high-content quaternary ammonium salt (powder, crystal, paste), low-content quaternary ammonium salt (liquid, paste), special quaternary ammonium salt, and quaternary ammonium salt. Alkali, etc., and can provide customized services for related products.
Our main R&D directions are: oilfield chemicals and quaternary ammonium salt downstream products (such as emulsifiers for pesticides, disinfectants for aquatic products, surfactants with special requirements for daily chemicals, etc.) and new innovative structures Surfactant. Therefore, in addition to supplying conventional surfactant products, we can also customize various surfactant products with special requirements according to customer needs to meet the special needs of various industries for surfactants.
Market News:One of the main benefits of biocatalysis is that it increases conversion efficiency for significantly higher yields with fewer by-products, equating to faster and more cost-effective production. 7-(S)-(((Naphthalene-2-carbonyl)amino)methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2, 3-c]pyridine-3-carboxylic acid manufacturer.The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1 2-hydroperoxy-2-(1-oxidaneyl)undecaoxacycloundecane supplier.In the trial, 362 eligible patients were randomised (1:1) and received a fixed-dose intravenous infusion of 300mg anifrolumab or placebo every four weeks. (4-Methoxy-phenylglyoxal)-(4-acetamino-anil) producer.